Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
Stopped The sponsor sold the drug TALADEGIB to another company during the trial and thereafter no drug was available. The sponsor made a decision to stop development of this drug Taladegib.
Conditions
- Gastroesophageal Junction Adenocarcinoma
- Stage IB Esophageal Adenocarcinoma AJCC v7
- Stage II Esophageal Adenocarcinoma AJCC v7
- Stage IIA Esophageal Adenocarcinoma AJCC v7
- Stage IIB Esophageal Adenocarcinoma AJCC v7
- Stage IIIA Esophageal Adenocarcinoma AJCC v7
- Stage IIIB Esophageal Adenocarcinoma AJCC v7
Interventions
- DRUG: Carboplatin
- RADIATION: External Beam Radiation Therapy
- OTHER: Laboratory Biomarker Analysis
- DRUG: Paclitaxel
- DRUG: Taladegib
Sponsor
M.D. Anderson Cancer Center
Collaborators